ERIC Number: EJ862676
Record Type: Journal
Publication Date: 2009-Dec
Abstractor: As Provided
Reference Count: 0
Open-Label Memantine in Fragile X Syndrome
Erickson, Craig A.; Mullett, Jennifer E.; McDougle, Christopher J.
Journal of Autism and Developmental Disorders, v39 n12 p1629-1635 Dec 2009
Glutamatergic dysfunction is implicated in the pathophysiology of fragile X syndrome (FXS). The purpose of this pilot study was to examine the effectiveness and tolerability of memantine for a number of target symptoms associated with FXS. Medical records describing open-label treatment with memantine in 6 patients with FXS and a comorbid diagnosis of PDD were reviewed. Six patients received memantine over a mean 34.7 weeks of treatment. Four of 6 (67%) patients showed global clinical benefit on ratings with the CGI-I. Symptom specific rating scales, however, showed no statistically significant improvement. Two patient developed treatment-limiting irritability on memantine. Memantine was modestly effective in several patients with FXS. Further systematic study is warranted.
Descriptors: Mental Retardation, Rating Scales, Patients, Genetic Disorders, Physiology, Drug Therapy, Symptoms (Individual Disorders), Pervasive Developmental Disorders, Behavior Modification, Pharmacology
Springer. 233 Spring Street, New York, NY 10013. Tel: 800-777-4643; Tel: 212-460-1500; Fax: 212-348-4505; e-mail: firstname.lastname@example.org; Web site: http://www.springerlink.com
Publication Type: Journal Articles; Reports - Evaluative
Education Level: N/A
Authoring Institution: N/A